Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy

Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Ryan Sun

Consulting or Advisory Role: Boehringer Ingelheim

Research Funding: Sanofi

Jason Willis

Honoraria: Cor2Ed

Kanwal P. Raghav

Consulting or Advisory Role: AstraZeneca, Bayer, Eisai, Daiichi Sankyo, Seattle Genetics

Speakers' Bureau: Bayer

Research Funding: Bayer (Inst), Roche/Genentech (Inst), Guardant Health (Inst), Daiichi Sankyo/Astra Zeneca (Inst), HiberCell (Inst), Merck Serono (Inst)

Van K. Morris

Consulting or Advisory Role: Incyte, Boehringer Ingelheim, Axiom Healthcare Strategies, BioMedical Insights, Bicara Therapeutics

Research Funding: Bristol Myers Squibb (Inst), EMD Serono (Inst), Immatics, Pfizer (Inst), BioNTech (Inst), Bicara Therapeutics (Inst)

John P. Shen

Stock and Other Ownership Interests: Agios, Syndax

Consulting or Advisory Role: Engine Biosciences

Research Funding: Celsius Therapeutics

Eduardo Vilar

Consulting or Advisory Role: Janssen Research & Development, Recursion Pharmaceuticals, Guardant Health

Research Funding: Janssen Research & Development

Patents, Royalties, Other Intellectual Property: The University of Texas MD Anderson Cancer Center, Vilar E, Wu W, Katayama H, Hanash S, Bommi P. Methods for Prognosing, Diagnosing, and Treating Colorectal Cancer, United States, 63/152,751, 2/23/2021, Filed (Provisional), The University of Texas MD Anderson Cancer Center, Vilar E, Chang K, Wu W, Bowen CM, Sinha K. Methods and Compositions Comprising MHC Class I Peptides, United States, 63/171,137, 4/6/2021, Filed (Provisional)

Travel, Accommodations, Expenses: Janssen Research & Development

Marko Rehn

Employment: Amgen

Stock and Other Ownership Interests: Amgen

Agnes Ang

Employment: Amgen

Stock and Other Ownership Interests: Amgen (Inst)

Research Funding: Amgen

Teresa Troiani

Consulting or Advisory Role: BMS Italy, Novartis, Servier, Pfizer

Scott Kopetz

Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines

Consulting or Advisory Role: Genentech, EMD Serono, Merck, Holy Stone Healthcare, Novartis, Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Bayer Health, Pierre Fabre, EMD Serono, Redx Pharma, Ipsen, Daiichi Sankyo, Natera, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, AbbVie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotech, Bicara Therapeutics, Endeavor BioMedicines, Numab, Johnson & Johnson/Janssen, Genomic Health, Frontier Medicines, Replimune, Taiho Pharmaceutical

Research Funding: Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, Lilly, Daiichi Sankyo

No other potential conflicts of interest were reported.

留言 (0)

沒有登入
gif